{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:09:45Z","timestamp":1793149785085,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtct.2023.03.018","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T14:35:01Z","timestamp":1679495701000},"page":"392.e1-392.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-8519","authenticated-orcid":false,"given":"Rutger","family":"Callens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-2266","authenticated-orcid":false,"given":"Sofie","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Delie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Lodewyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-1279","authenticated-orcid":false,"given":"Marijke","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Kerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Padalko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.03.018_bib0001","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.018_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0003","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.018_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0005","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.018_bib0006","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.jtct.2023.03.018_bib0007","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus (CMV) prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation (HCT): a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.03.018_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.018_bib0010","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0012","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-\u03b3-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0013","unstructured":"Commissie Praktische Tuberculosebestrijding (CPT). Richtlijn Diagnostiek (Latente) Tuberculose-infectie (LTBI). Available at: https:\/\/www.kncvtbc.org\/uploaded\/2019\/03\/4.2_LTBI_volledig.pdf. Revisie 2020:46. Accessed November 19, 2022"},{"key":"10.1016\/j.jtct.2023.03.018_bib0014","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jtct.2023.03.018_bib0015","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV QuantiFERON gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2023.03.018_bib0016","first-page":"9:88","article-title":"Comparison of three cellular assays to predict the course of CMV infection in liver transplant recipients","author":"Gliga","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jtct.2023.03.018_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jtct.2023.03.018_bib0018","doi-asserted-by":"crossref","first-page":"e13786","DOI":"10.1111\/tid.13786","article-title":"QuantiFERON-cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Thompson","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.018_bib0019","doi-asserted-by":"crossref","first-page":"e74744","DOI":"10.1371\/journal.pone.0074744","article-title":"Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV\u00ae assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications","volume":"8","author":"Tey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2023.03.018_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcv.2016.03.026","article-title":"QuantiFERON-CMV assay in allogenic stem cell transplant patients","volume":"79","author":"Bono","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jtct.2023.03.018_bib0021","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3343\/alm.2017.37.3.277","article-title":"Clinical usefulness of monitoring cytomegalovirus-specific immunity by QuantiFERON-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients","volume":"37","author":"Lee","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jtct.2023.03.018_bib0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.01.002","article-title":"Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real-time PCR","volume":"99-100","author":"Krawczyk","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jtct.2023.03.018_bib0023","doi-asserted-by":"crossref","first-page":"e13795","DOI":"10.1111\/tid.13795","article-title":"Belatacept may result in profound and persistent loss of cytomegalovirus-specific cell-mediated immunity: a case report","volume":"24","author":"Kleiboeker","year":"2022","journal-title":"Transpl Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:21Z","timestamp":1763003361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723011776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666636723011776"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}